Pdf malignant hyperthermia is a potentially lethal inherited disorder characterized by disturbance of calcium homeostasis in skeletal muscle. Patients known to be susceptible to malignant hyperthermia may actually undergo anesthesia several times before a clinical episode occurs. Jul 24, 2020 malignant hyperthermia mh is a lifethreatening clinical syndrome of hypermetabolism involving the skeletal muscle. Malignant hyperthermia mh is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible.
Consensus guidelines on perioperative management of. Taking a personal and family history of anaesthetic problems is a mandatory part of preoperative assessment forall patients requiring general or regional anaesthesia. Symptoms include muscle rigidity, high fever, and a fast heart rate. Jun 30, 2014 the european malignant hyperthermia group has established guidelines for molecular genetic testing of malignant susceptibility and for invitro contracture testing. Arterial blood gas analysis hypercarbia with respiratory and metabolic acidosis. Bagnola, pharmd, bcps m alignant hyperthermia mh was. Guideline malignant hyperthermia association of surgical. Malignant hyperthermia diagnosis and treatment mayo clinic. All departments of anesthesia should have a policy and procedures manual for the treatment of an mh reaction as well as the anesthetic. Recommendations for the preparation of anesthesia workstations to anesthetize mh susceptible. Principal findings malignant hyperthermia is a genetic disorder of skeletal muscle cells affecting myoplasmic.
Malignant hyperthermia mh is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to. Bonet, msn, bhsa, rn, cnor objectives outline the history of mh as a known disorder. Jan 01, 2021 consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the european malignant hyperthermia group author links open overlay panel henrik ruffert 1 2 borge bastian 2 diana bendixen 3 thierry girard 4 sebastian heiderich 5 anna hellblom 6 philip m. Crisis management of malignant hyperthermia in the or. We will then discuss the perioperative management, referral and diagnosis of suspected mh. Faced with a malignant hyperthermia crisis, the immediate access to sufficient dantrolene is essential to achieve the best possible outcome for the patient. Thus,itiscriticalthat awareness and prevention of the condition play significant roles in the management of malignant hyperthermia.
Preparation of anesthesia workstations to anesthetize mh susceptible patients. Malignant hyperthermia symptoms, diagnosis and treatment. Reprinted with permission from aorn, inc, denver, co. Guidelines for the management of a malignant hyperthermia. It is not an exhaustive prescription for all mh crises it represents the views of the mhanz and has been endorsed by the australian and new zealand college of anaesthetists as part of the mh resource kit 2018. Guidelines for management of a malignant hyperthermia mh crisis an evolving mh reaction and exclusion of other differential causes. Suggested guidelines for management of the pregnantpatient not believed to be at risk for mh, but whose partner is susceptible to malignant hyperthermia. Malignant hyperthermia mh is a rare, inherited skeletal muscle syndrome that presents as a. Oct 24, 2019 in one confirmed case with mutation analysis reported to the malignant hyperthermia association of the united states mhaus hotline, the patient had undergone approximately 30 general anesthetics prior to developing mh. This is made far easier through effective teamwork and specific task allocation. Malignant hyperthermia is a potentially lethal inherited disorder characterized by disturbance of calcium homeostasis in skeletal muscle. Malignant hyperthermia a life threatening reaction that is most often triggered by the use of inhalational anesthetics estimated incidence of 1 in 5,000 to 1 in.
A mh reaction is characterized by hypermetabolism resulting in hyperthermia, increased oxygen consumption, increased carbon dioxide co 2 production, hyperkalaemia, and metabolic acidosis. Necessary supplies for multiple setups 36 vials dantrolene sodium, 20 mg 100 ml bottles of sterile water for injection 6 luerlock vented dispensing pins 6 luerlock 60 ml syringes. The successful management of a malignant hyperthermia crisis requires multiple simultaneous treatment actions. Onset can be within minutes of induction or may be insidious. It is triggered in susceptible individuals primarily by the volatile inhalational anesthetic agents and the muscle relaxant succinylcholine, though other drugs have also been implicated as potential triggers. The malignant hyperthermia association of the united states mhaus4 recommends that the mh cart be stocked with at least 36 vials of dantrolene and enough sterile water for dilution.
Also discussed are current standardsguidelines and recommenda tions for physicians and support personnel re garding facility and equipment requirements and malignant hyperthermia preparedness in office. Malignant hyperthermia 2020 hopkins anaesthesia wiley. Malignant hyperthermia mh department of clinical effectiveness v3 approved by the executive committee of the medical staff on 07212020. Malignant hyperthermia is marked by high fever, muscle rigidity, rhabdomyolysis, and respiratory and. Malignant hyperthermia mh is a rare disorder of skeletal muscles related to a high release of calcium from the sarcoplasmic reticulum which leads to muscle rigidity in many cases and hypermetabolism. It is an inherited disease usually triggered by the administration of volatile inhalational anesthetics andor succinylcholine, a muscle relaxant. Larach mg, localio ar, allen gc, denborough ma, ellis fr, gronert ga, kaplan rf, muldoon sm, nelson te, ording h, rosenberg. Consensus statement of the malignant hyperthermia association of the united states on unresolved clinical questions concerning the management of patients with malignant hyperthermia. In order to set the scene and focus of the article it is useful to initially provide some definitions. These guidelines were developed by members of the european malignant hyperthermia group based on available literature and a formal consensus process. Guidelines for management of a malignant h yperthermia mh crisis an evolving mh reaction and exclusion of other differential causes.
Hopkins malignant hyperthermia investigation unit, university ofleeds, leeds, uk brjanaesth 2000. We will then discuss the perioperative management, referral. This severe reaction typically includes a dangerously high body temperature, rigid muscles or spasms, a rapid heart rate, and other symptoms. An important complication of anesthesia is malignant hyperthermia, an autosomal dominant disorder of the regulation of calcium transport in the skeletal muscles resulting in a hypermetabolic crisis. This is made far easier through effective teamwork and specific task. Updated guide for the management of malignant hyperthermia. Malignant hyperthermia association of the united states 1 north main street po box 1069 sherburne, ny 460 6076747901 mhaus has established a hotline to assist a surgical team in the immediate treatment of a patient. Malignant hyperthermia symptoms and causes mayo clinic. The latter aspect includes guidance on the use of activated charcoal. Rigidity of the jaw muscles after administration of.
Pdf malignant hyperthermia mh is a pharmacogenetic disorder of skeletal muscle. Review gmha guidelines for the care of mh patients. Pdf developing effective drills in preparation for a. Also discussed are current standardsguidelines and recommenda tions for physicians and support personnel re garding facility and equipment requirements and malignant hyperthermia preparedness in office based surgery and anesthesia. Dantrolene is currently the only known treatment for a mh crisis. Jsa guideline for the management of malignant hyperthermia. Malignant hyperthermia mh can be fatal if the crisis is not appropriately treated. Jun 23, 2020 faced with a malignant hyperthermia crisis, the immediate access to sufficient dantrolene is essential to achieve the best possible outcome for the patient.
Approved october 2005 revised april 9, 2018 guidelines for. These include a raised creatine kinase level, elevated potassium, increased phosphate leading to decreased calcium andif determinedraised myoglobin. The initial treatment of acute malignant hyperthermia crisis is the immediate discontinuation of triggering agents, hyperventilation, administration of dantrolene in doses of 2. Malignant hyperthermia mh is a rare, inherited musculoskeletal syndrome that presents as a hypermetabolic reaction triggered by exposure to volatile anesthetic gases e. Availability of dantrolene for the management of malignant. Malignant hyperthermia mh is a lifethreatening condition that occurs under general anaesthesia. Malignant hyperthermia mh is an inherited disorder of skeletal muscle that manifests clinically as a hypermetabolic crisis when a susceptible individual receives a halogenated inhalational anesthetic agent or succinylcholine. Malignant hyperthermia is diagnosed on clinical grounds, but various laboratory investigations may prove confirmatory. Current concepts in the understanding of malignant. Initial steps involve stopping the delivery of the triggering agent, such as sevoflurane, isoflurane, or desflurane. Malignant hyperthermia crisis can occur 36 hours after anesthesia applications. Malignant hyperthermia susceptibility and related diseases. Malignant hyperthermia is a progressive, lifethreatening. Guidelines for the management of a malignant hyperthermia crisis.
Malignant hyperthermia susceptible patients should receive anaesthesia that is free of triggering agents using a prepared anaesthetic workstation. Definition, relationship to malignant hyperthermia mh, and management developed in 2018 background. Malignant hyperthermia crisis preparedness and treatment. Mmr can be generally defined as a marked difficulty in manual mouth opening that interferes with and impedes direct.
Diagnosis and treatment of druginduced hyperthermia. Malignant hyperthermia malignant hyperpyrexia medcrine. Without prompt treatment, the complications caused by malignant hyperthermia. Consensus guidelines on perioperative management of malignant. Malignant hyperthermia association of the united states. Diagnosis and management of malignant hyperthermia oxford. Unsafe anesthetic agents for malignant hyperthermia susceptible patients inhaled general anesthetics desflurane enflurane isofluran. Malignant hyperthermia may first occur after repeated exposure to anesthesia, or it may occur postoperatively in the postanesthesia care unit pacu or the intensive care unit icu. The principles of management of a malignant hyperthermia reaction are to immediately reverse the. The mortality from mh in the uk is 4%, 6 while the most recent data from the usa suggest that the mortality from mh reactions there has increased over the last 15 years to 612%. These guidelines cover standard operating procedures for managing such a crisis, task allocations, and recommended contents for your malignant hyperthermia management kit.
Successful management of malignant hyperthermia depends upon early diagnosis and treatment. Tachycardia, mixed respiratory and metabolic acidosis are present due to the hypermetabolic state. Management of postacute phase of malignant hyperthermia due to risk of recurrence, observe patient in icu for at least 24 hours give dantrolene 1 mgkg q 46 hours, or 0. Report to malignant hyperthermia association of the united states mhaus call mh hotline 18006449737 provide patient education regarding mh and future precautions.
Malignant hyperthermia mh is a rare disorder of skeletal muscles related to a high. Pdf heat production and the importance of temperature. Malignant hyperthermia mh is a potentially lethal pharmacogenetic disorder that. Experiencing malignant hyperthermia in the operating room. Malignant hyperthermia is a rare but lifethreatening emergency. Clinical symptoms of malignant hyperthermia, diagnostic criteria, and current therapeutic guidelines, as well as adequate management of anesthesia in patients susceptible to malignant hyperthermia. Malignant hyperthermia has an underlying genetic basis, and genetically susceptible individuals are at risk of developing malignant hyperthermia if they are exposed to any of the potent inhalational anaesthetics or.
Mar 29, 2018 purpose this continuing professional development module aims to prepare anesthesiologists for the timely recognition and management of a malignant hyperthermia mh reaction, which is crucial for averting its lifethreatening complications and ultimately for the patients survival. The principles of management of a malignant hyperthermia reaction are to immediately reverse the reaction and treat the consequences of the reaction. Far more often, malignant hyperthermia will be diagnosed in the operating room with intensivists involved in providing followup care. Jan 29, 2020 malignant hyperthermia mh is a syndrome that typically follows exposure to potent inhalation anaesthetics andor succinylcholine suxamethonium in susceptible individuals. Diagnosis and management of malignant hyperthermia bja. The hotline is staffed by anesthesiologist volunteers who are experts in the treatment of. Identify methods of treating a patient during an mh crisis. The hotline is staffed by anesthesiologist volunteers who are experts in. Malignant hyperthermia crisis association of anaesthetists. Crisis management of malignant hyperthermia in the or patricia c. A malignant hyperthermia mh crisis is a medical emergency. Oct 27, 2020 clinical symptoms of malignant hyperthermia, diagnostic criteria, and current therapeutic guidelines, as well as adequate management of anesthesia in patients susceptible to malignant hyperthermia. The successful management of a malignant hyperthermia mh crisis requires multiple simultaneous treatment actions. Three approaches to reversing the malignant hyperthermia process should be applied together.
With proper interventions, the mortality rate can be taken down to 5% from 80%. Most people who are susceptible are generally otherwise unaffected when not. In a patient with suspected mh, the mechanism of calcium release fro. Malignant hyperthermia 2020 association of anaesthetists. Malignant hyperthermia management approach bmj best. To give the patient the best possible chance for a successful outcome, a swift, coordinated, multidisciplinary team response is necessary. Describe the steps in the treatment of malignant hyperthermia. However, malignant hyperthermia crises are rare, and there may be administrative pressures to limit the amount of dantrolene stocked or, in some countries, not to stock dantrolene at all. Increasing endtidal co 2 is usually the first sign of mh. A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the united states. Complications can include muscle breakdown and high blood potassium. Malignant hyperthermia is diagnosed based on signs and symptoms, monitoring during and immediately after anesthesia, and lab tests to identify complications. However, malignant hyperthermia crises are rare, and there may be administrative pressures to limit the amount of dantrolene stocked or, in som. Malignant hyperthermia mh was the name given to a type of severe reaction under general anaesthesia that was first described in 1960.
Malignant hyperthermia mh is a rare, but lifethreatening, autosomaldominant inherited disorder that may lead to metabolic crisis of skeletal. Discontinue all volatile inhalational agents and succinylcholine. The anesthetic management of an mh crisis is among the most intense clinical challenges an anesthesia provider can encounter table 2. Recall nursing staff responsibilities for patient care. Nevertheless, strong consideration for proper temperature management of the known or suspected mh patient, in all clinical areas pre, intra and postoperative, is critical. We will then discuss the perioperative management, referral, and diagnosis of suspected mh. Malignant hyperthermia identification and management. Malignant hyperthermia protocol for suspected mh event mhaus protocol. Aorn association of perioperative registered nurse malignant hyperthermia guide defines the responsibilities of nurses during the crisis. Malignant hyperthermia is defined in the international classification of diseases as a progressive lifethreatening hyperthermic reaction occurring during general anaesthesia.
563 1608 825 975 1252 505 223 1415 587 554 318 649 296 774 680 816 381 146 371 1188